LINFOMAS Y TRASPLANTES
![Foto de LINFOMAS Y TRASPLANTES](/img/grupo.png)
![Foto de Hospital Universitario Virgen del Rocío](/img/noimage_org.png)
Hospital Universitario Virgen del Rocío
Sevilla, EspañaPublikationen in Zusammenarbeit mit Forschern von Hospital Universitario Virgen del Rocío (62)
2024
-
Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma
Clinical Cancer Research, Vol. 30, Núm. 10, pp. 2085-2096
-
Ofatumumab as part of reduced intensity conditioning in high risk B-cell lymphoma patients: final long-term analysis from a prospective multicenter Phase-II Trial
Bone Marrow Transplantation
-
Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis in HLA-Matched and Haploidentical Donor Transplantation for Patients with Hodgkin Lymphoma: A Comparative Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation
Transplantation and Cellular Therapy, Vol. 30, Núm. 2, pp. 210.e1-210.e14
2023
-
Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy
Transplantation and Cellular Therapy, Vol. 29, Núm. 7, pp. 430-437
-
Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma
Haematologica, Vol. 108, Núm. 1, pp. 110-121
-
Correction: Role of allogeneic hematopoietic cell transplant for relapsed/refractory aggressive B-cell lymphomas in the CART era (Bone Marrow Transplantation, (2023), 58, 6, (673-679), 10.1038/s41409-023-01949-x)
Bone Marrow Transplantation
-
Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study
The Lancet Oncology, Vol. 24, Núm. 8, pp. 913-924
-
Impact of SCHOLAR-1 Criteria on Chimeric Antigen Receptor T Cell Therapy Efficacy in Aggressive B Lymphoma: A Real-World GELTAMO/GETH Study
Transplantation and Cellular Therapy, Vol. 29, Núm. 12, pp. 747.e1-747.e10
-
Integrating biological HLA-DPB1 mismatch models to predict survival after unrelated hematopoietic cell transplantation
Haematologica
-
Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: A phase 2 study from GELTAMO
British Journal of Haematology, Vol. 203, Núm. 2, pp. 202-211
-
Peripheral T-cell lymphoma with a T follicular-helper phenotype: A different entity? Results of the Spanish Real-T study
British Journal of Haematology, Vol. 203, Núm. 2, pp. 182-193
-
Role of allogeneic hematopoietic cell transplant for relapsed/refractory aggressive B-cell lymphomas in the CART era
Bone Marrow Transplantation, Vol. 58, Núm. 6, pp. 673-679
-
Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic GVHD: A Report of Two Phase I/II Trials
Clinical Cancer Research, Vol. 29, Núm. 20, pp. 4057-4067
2022
-
Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma; Insights into Its Potential Role in the Era of New Immunotherapeutic and Targeted Therapies: The GETH/GELTAMO Experience
Cancers, Vol. 14, Núm. 11
-
Autologous stem-cell transplantation as consolidation of first-line chemotherapy in patients with peripheral T-cell lymphoma: a multicenter GELTAMO/FIL study
Haematologica, Vol. 107, Núm. 11, pp. 2675-2684
-
Best Treatment Option for Patients With Refractory Aggressive B-Cell Lymphoma in the CAR-T Cell Era: Real-World Evidence From GELTAMO/GETH Spanish Groups
Frontiers in Immunology, Vol. 13
-
Comparison of outcomes for HLA-matched sibling and haplo-identical donors in Myelodysplastic syndromes: report from the chronic malignancies working party of EBMT
Blood Cancer Journal, Vol. 12, Núm. 9
-
Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 40, Núm. 11, pp. 1196-1205
-
Open-label, phase 2 study of blinatumomab after frontline R-chemotherapy in adults with newly diagnosed, high-risk DLBCL
Leukemia and Lymphoma, Vol. 63, Núm. 9, pp. 2063-2073
-
Phase II Trial of Allogeneic Transplantation Plus Novel Drugs in Multiple Myeloma: Effect of Intensifying Reduced-Intensity Conditioning with Bortezomib and Adding Maintenance Treatment
Transplantation and Cellular Therapy, Vol. 28, Núm. 5, pp. 258.e1-258.e8